Adalimumab for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 5, Issue 1, 2009, Pages 19-26

  Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adalimumab; Methotrexate; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DENOSUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INFECTION; INJECTION SITE REACTION; JOINT DESTRUCTION; LONG TERM CARE; PHARMACODYNAMICS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 67650015746     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.5.1.19     Document Type: Review

References (47)

1. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46, 862 (2002).
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 46, 328-346 (2002).
3. Weinblatt ME, Kaplan H, Germain BE et al. Methotrexate in rheumatoid arthritis. A 5-year prospective multicenter study. Arthritis Rheum. 37, 1492-1498 (1994).
4. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 35, 138-145 (1992).
5. O'Dell J. Treating rheumatoid arthritis early: a window of opportunity. Arthritis Rheum. 46, 283-285 (2002).
6. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann. Rheum. Dis. 63, 627-633 (2004).
7. Maini RN, St Clair EW, Breedveld FC et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT study Group. Lancet 354, 1932-1939 (1999).
8. den Broeder A, van de Putte L, Rau R et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor- alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. 29, 2288-2298 (2002).
9. Genovese MC, Kremer JM. Treatment of rheumatoid arthritis with etanercept. Rheum. Dis. Clin. N. Am. 30, 311-328 (2004).
10. Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 cell activation molecule. Science 257, 792-795 (1992).
11. Edwards JCW, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology 44, 151-156 (2005).
12. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A mutlicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
13. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, a IL-6 inhibitor (SAMURAI); evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 2262-11167 (2007).
14. Kay J, Matterson FC, Dasgupta B et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate; a randomized, doubleblinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58, 964-975 (2008).
15. Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action; a comprehensive review. Pharmacol. Ther. 117, 244-279 (2007).
16. Salfeld J, Kaymakcalan Z, Tracey D et al. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum. 41(Suppl.), S57 (1998).
17. Weisman MH, Morelan LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate; a pilot study. Clin. Ther. 25, 1700-1721 (2003).
18. van de Putte LB, Rau B, Breedveld FC et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis; a 12 week, Phase II study. Ann. Rheum. Dis. 62(12), 1168-1177 (2003).
19. van de Putte LB, Atlkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508-516 (2004).
20. Miyasaka N, The Change Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation; the CHANGE study. Mod. Rheumatol. 18, 252-262 (2008).
21. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate; the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
22. Weinblatt, ME, Keystone EC, Furst DE et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis; ARMADA 4 year extended study. Ann. Rheum. Dis. 65, 753-759 (2006).
23. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week-trial. Arthritis Rheum. 50, 1400-1411 (2004).
24. Breedveld F, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).
25. Kimel M, Cifaldi M, Chen N et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J. Rheumatol. 35, 206-215 (2008).
26. Burmester GR, Mariette X, Montecucco C et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 66, 732-739 (2007).
27. Bombardieri S, Ruiz AA, Fardellone P et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatol. 46, 1191-1199 (2007).
28. Wick MC, Ernestam S, Lindblad S et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results for the STURE regsistry at Karolinskia University Hospital. Scand. J. Rheumatol. 34, 353-358 (2005).
29. Nikas SN, Voulgari PV, Alamanos Y et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann. Rheum. Dis. 65, 257-260 (2006).
30. Hjardem E, Ostergaard M, Podenphant J et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor a inhibitor? Ann. Rheum. Dis. 66, 1184-1189 (2007).
31. Karisson JA, Kristensen LE, Kapetanovic MC et al. Treatment response to a second or third TNF-inhibitor in RA; results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47, 507-513 (2008).
32. van der Bijl AE, Breedveld FC, Antoni CE et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin. Rheumatol. 27, 1021-1028 (2008).
33. Walsh CA, Minnock P, Slattery C et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 46, 1148-1152 (2007).
34. Kievit W, Adang EM, Fransen J et al. The effectiveness and medication costs of three anti-TNF agents (a) in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann. Rheum. Dis. 67(9), 1229-1234 (2008).
35. Furst DE, Schiff MH, Fleischman RM et al. Adalimumab, a fully human and tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30, 2563-2571 (2003).
36. Burmester GR, Ferraccioli G, Flipo RM et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 59, 32-41 (2008).
37. Schiff MH, Burmester GR, Kent JD et al. Safety analysis of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 889-894 (2006).
38. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921-926 (2007).
39. Kaine JL, Kivitz AJ, Birbara C et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34, 272-279 (2007).
40. Toonen EJM, Coenen MJH, Kievit W et al. The tumour necrosis factor receptor superfamily member to 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 67, 1174-1177 (2008).
41. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacepts in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 1443, 865-870 (2006).
42. Emery P, Kosinski M, Li T et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J. Rheumatol. 33, 681-689 (2006).
43. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIb randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006).
44. Doemer T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr. Opin. Rheumatol. 20, 263-268 (2008).
45. Mima T, Nishimoto N. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol. 4, 165-172 (2008).
46. Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum. 58(5), 1299-1309 (2008).
47. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10(1), R14 (2008).